Novo Shares Fall

On 12 Apr 2026, shares plunged by as much as 20 % in early trading after the company warned that 2026 sales and earnings could fall 5 – 13 % and that current‑year revenue could decline up to 13 %. The downtick coincided with a broader sell‑off in the obesity‑drug sector triggered by rivals Eli Lilly’s Mounjaro, which reported a 110 % rise in sales in the last quarter of 2025 and is forecast to generate $80 – $83 bn in 2026. Novo’s outlook cites intensifying U.S. pricing pressure, the MFN pricing arrangement, and the expiry of the semaglutide molecule in Brazil, Canada and China. The company faces generic Ozempic versions overseas and competition from Eli Lilly’s Zepbound and lower‑priced telehealth alternatives.